1. Date of download: 11/13/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain MetastasesA Randomized Controlled Trial JAMA. 2006;295(21):2483-2491. doi:10.1001/jama.295.21.2483 SRS indicates stereotactic radiosurgery; WBRT, whole-brain radiation therapy. Figure Legend:

2. Date of download: 11/13/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain MetastasesA Randomized Controlled Trial JAMA. 2006;295(21):2483-2491. doi:10.1001/jama.295.21.2483 The mean survival time was 7.5 months for patients receiving whole-brain radiation therapy (WBRT) plus stereotactic radiosurgery (SRS) and 8.0 months for patients receiving SRS alone. This difference was not significant (P =.42). There was a statistically significant decrease in brain tumor recurrence in the WBRT+SRS group (P =.003). Figure Legend:

3. Date of download: 11/13/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain MetastasesA Randomized Controlled Trial JAMA. 2006;295(21):2483-2491. doi:10.1001/jama.295.21.2483 There was a statistically significant increase in local tumor control in patients receiving whole-brain radiation therapy (WBRT) plus stereotactic radiosurgery (SRS) (P =.002). Figure Legend: